Diabetes News and Research

Latest Diabetes News and Research

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

AstraZeneca and the University of Virginia (UVa) in Charlottesville, today announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

15 Dec 2009

Positive results from study comparing exenatide once weekly to BYETTA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes.

15 Dec 2009

Pfizer to co-promote Actos with Tianjin Takeda Pharmaceuticals in China

Takeda Pharmaceutical Company Limited (“Takeda”) and Pfizer Inc. (“Pfizer”) announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda’s Actos® (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China.

15 Dec 2009

Novartis submits JOULFERON MAA to the EMEA

Human Genome Sciences, Inc. today announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C. In November 2009, HGS submitted a Biologics License Application (BLA) for ZALBIN to the FDA in the United States.

15 Dec 2009

Medicare power mobility remains a viable option for beneficiaries

Across America, seniors, together with their families and caregivers, are making difficult decisions about the future. Did that last emergency room visit after a fall mean it's time to consider nursing homes? How much longer can their loved one remain safely in their own home or apartment?

15 Dec 2009

New technique may help diagnose treatments for Alzheimer's, diabetes and cancer

Chemists and biologists from the University of Bath have developed a new technique that could be used to diagnose and develop treatments for age-related conditions like Alzheimer's disease, diabetes and cancer.

15 Dec 2009

Findings suggest variations in accelerated aging disorders

UT Southwestern Medical Center researchers have provided the most extensive account to date of the unique observable characteristics seen in patients with an extremely rare premature aging syndrome.

15 Dec 2009

Study to determine link between insulin glargine and cancer

Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications. However, these studies were unable to control for important factors such as obesity that may have driven the association.

15 Dec 2009

Novo Nordisk initiates share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

15 Dec 2009

People with periodontal disease are at high risk for diabetes, survey finds

The study, led by Dr. Shiela Strauss, Associate Professor of Nursing and Co-Director of the Statistics and Data Management Core for NYU's Colleges of Dentistry and Nursing, examined data from 2,923 adult participants in the 2003-2004 National Health and Nutrition Examination Survey who had not been diagnosed with diabetes.

15 Dec 2009

CureDM receives patent allowance for novel islet neogenesis program

CureDM, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering a Human proIslet Peptide (HIP) and methods related to its use and administration for treating type 1 diabetes.

15 Dec 2009

Geron’s request for declaration of interference regarding Novocell' U.S. Patent No. 7,510,876 granted

Geron Corporation today announced that the U.S. Patent and Trademark Office, Board of Patent Appeals and Interferences, has granted Geron’s request to declare an interference between a patent application owned by Geron and U.S. Patent No. 7,510,876 (the ‘876 patent) owned by Novocell, Inc.

15 Dec 2009

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease.

15 Dec 2009

Anthem Blue Cross to receive Tri-County Commercial contract renewal award

Anthem Blue Cross announced today that the California Department of Health Care Services intends to award Anthem the Tri-County Commercial contract renewal to provide Medi-Cal benefits to residents in the Fresno, Kings and Madera Counties.

15 Dec 2009

Poor access to safe and nutritious foods can pose serious health challenges for diabetes patients

Preparing a healthy meal loaded with fresh vegetables seems like an easy thing to do. But for some people living with diabetes, having access to nutritious food can be difficult --- and may have a detrimental effect on their health and well-being, according to a new study led by Ryerson University.

15 Dec 2009

Demystifying Psychiatry: A resource for patients and families

Psychiatric disorders are underdiagnosed, poorly treated and highly stigmatized, according to psychiatrists Charles F. Zorumski, M.D., and Eugene H. Rubin, M.D., Ph.D. So these Washington University physicians have written a book to address those problems.

15 Dec 2009

Bio-Quant becomes wholly-owned subsidiary of NexMed

NexMed, Inc., a developer of products based on the NexACT® technology, today announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Upon closing, Bio-Quant became a wholly-owned subsidiary of NexMed.

15 Dec 2009

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers at the Los Angeles Biomedical Research Institute (LA BioMed) expect to receive more than $4.5 million in grants from the American Recovery and Reinvestment Act (Recovery Act.), including nearly $1 million from the highly competitive Challenge Grant program for a study that seeks to reduce the number of children who die from Sudden Infant Death Syndrome, it was announced today.

15 Dec 2009

Amgen receives worldwide rights to Array’s small-molecule glucokinase activator program

Array BioPharma Inc. and Amgen Inc.(NASDAQ: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.

14 Dec 2009

Postmenopausal women who take antidepressants face increased risk for stroke and death

Postmenopausal women who take antidepressants face a small but statistically significant increased risk for stroke and death compared with those who do not take the drugs. The new findings are from the federally-funded, multi-institution, Women's Health Initiative Study sponsored by the National Institutes of Health, and the results are published in the December 14 online edition of Archives of Internal Medicine.

14 Dec 2009